Data from Phase 1 clinical trial in heavily pretreated patients with metastatic breast cancer showed DAN-222 was safe and well…
Read More
Series A financing led by Westlake Village BioPartners with participation from Corner Ventures, Alexandria Venture Investments, and Caltech Phase 1…